The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer

被引：0
|
作者：
Poma, A. [1 ]
Pasquini, G. [2 ]
Bruno, R. [3 ]
Ali, G. [3 ]
Proietti, A. [3 ]
Pecora, I. [2 ]
Petrini, L. [2 ]
Vasile, E. [2 ]
Chella, A. [4 ]
Fontanini, G. [1 ]
机构：
[1] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy
[2] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy
[3] Univ Hosp Pisa, Anat Pathol Unit, Pisa, Italy
[4] Azienda Osped Univ Pisana, Pneumo Oncol, Pisa, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
lung cancer; PD-L1; immunotherapy;
D O I：
10.1016/j.jtho.2019.08.969
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-66
引用
收藏
页码：S466 / S467
页数：2
相关论文
共 50 条
  • [1] PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
    Grigg, Claud
    Rizvi, Naiyer A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [2] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
    Kumar, Rajiv
    Collins, Dearbhaile
    Dolly, Saoirse
    McDonald, Fiona
    O'Brien, Mary E. R.
    Yap, Timothy A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124
  • [3] PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
    Munari, Enrico
    Zamboni, Giuseppe
    Marconi, Marcella
    Sommaggio, Marco
    Brunelli, Matteo
    Martignoni, Guido
    Netto, George J.
    Moretta, Francesca
    Mingari, Maria Cristina
    Salgarello, Matteo
    Terzi, Alberto
    Picece, Vincenzo
    Pomari, Carlo
    Lunardi, Gianluigi
    Cavazza, Alberto
    Rossi, Giulio
    Moretta, Lorenzo
    Bogina, Giuseppe
    ONCOTARGET, 2017, 8 (52): : 90123 - 90131
  • [4] Research progression of PD-1/PD-L1 in non-small cell lung cancer
    Xing Liu
    Xiaodong Xie
    Oncology and Translational Medicine, 2017, 3 (03) : 111 - 115
  • [5] Advanced non-small cell lung cancer: the role of PD-L1 inhibitors
    Heigener, David F.
    Reck, Martin
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1468 - S1473
  • [6] PD-L1 Immunohistochemistry as Biomarker in Non-Small Cell Lung Cancer (NSCLC)
    Krenbek, Dagmar
    Weidinger, Barbara
    Jarius, Christa
    Holzer, Sophia
    Fabican, Hannah
    Mohn-Staudner, Andrea
    Hochmair, Maximilian
    Chott, Andreas
    Setinekl, Ulrike
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S430 - S430
  • [7] Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Metro, Giulio
    Galetta, Domenico
    Toma, Alessandro De
    Cantale, Ornella
    Banini, Marco
    Friedlaender, Alex
    Pizzutillo, Pamela
    Garassino, Marina Chiara
    Addeo, Alfredo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1533 - +
  • [8] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [9] PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer
    Tsoukalas, Nikolaos
    Kiakou, Maria
    Tsapakidis, Konstantinos
    Tolia, Maria
    Aravantinou-Fatorou, Eleni
    Baxevanos, Panagiotis
    Kyrgias, Georgios
    Theocharis, Stamatios
    JOURNAL OF BUON, 2019, 24 (03): : 883 - 888
  • [10] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
12345